FANCD2 and endometrial carcinoma: Zhao et al. [61] demonstrated this on TCGA data; the same results were achieved with testing FANCD2 expressions or staining in breast cancer [62,63], endometrial carcinoma [64], colorectal cancer [65], esophageal squamous cell cancer [66], hepatocellular cancer [67], lung adenocarcinoma [68], and in pan-cancer settings [69].